智通财经APP讯,一品红(300723.SZ)公告,公司全资子公司广州一品红制药有限公司于近日收到国家药品监督管理局核准签发的关于盐酸丙卡特罗口服溶液的《药品注册证书》。该药品用于缓解下述疾病的呼吸道阻塞性障碍引起的呼吸困难等症状:支气管哮喘、慢性支气管炎、急性支气管炎、喘息性支气管炎。
智通财经APP讯,一品红(300723.SZ)公告,公司全资子公司广州一品红制药有限公司于近日收到国家药品监督管理局核准签发的关于盐酸丙卡特罗口服溶液的《药品注册证书》。该药品用于缓解下述疾病的呼吸道阻塞性障碍引起的呼吸困难等症状:支气管哮喘、慢性支气管炎、急性支气管炎、喘息性支气管炎。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.